Skip to content
Menu

Guggenheim Reiterates Buy on Assembly Biosciences, Maintains $43 Price Target

Benzinga Newsdesk 5 months ago

NewsPrice TargetReiterationAnalyst Ratings

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $43 price target.

Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $43 price target.

Read at benzinga.com